Burgaz, S.; García, C.; Gómez-Cañas, M.; Muñoz, E.; Fernández-Ruiz, J.
Development of An Oral Treatment with the PPAR-γ-Acting Cannabinoid VCE-003.2 Against the Inflammation-Driven Neuronal Deterioration in Experimental Parkinson’s Disease. Molecules 2019, 24, 2702.
https://doi.org/10.3390/molecules24152702
AMA Style
Burgaz S, García C, Gómez-Cañas M, Muñoz E, Fernández-Ruiz J.
Development of An Oral Treatment with the PPAR-γ-Acting Cannabinoid VCE-003.2 Against the Inflammation-Driven Neuronal Deterioration in Experimental Parkinson’s Disease. Molecules. 2019; 24(15):2702.
https://doi.org/10.3390/molecules24152702
Chicago/Turabian Style
Burgaz, Sonia, Concepción García, Maria Gómez-Cañas, Eduardo Muñoz, and Javier Fernández-Ruiz.
2019. "Development of An Oral Treatment with the PPAR-γ-Acting Cannabinoid VCE-003.2 Against the Inflammation-Driven Neuronal Deterioration in Experimental Parkinson’s Disease" Molecules 24, no. 15: 2702.
https://doi.org/10.3390/molecules24152702
APA Style
Burgaz, S., García, C., Gómez-Cañas, M., Muñoz, E., & Fernández-Ruiz, J.
(2019). Development of An Oral Treatment with the PPAR-γ-Acting Cannabinoid VCE-003.2 Against the Inflammation-Driven Neuronal Deterioration in Experimental Parkinson’s Disease. Molecules, 24(15), 2702.
https://doi.org/10.3390/molecules24152702
